NCT04752540View on ClinicalTrials.gov

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

October 24, 2021

Study Completion Date

October 24, 2021

Conditions

Hepatic Impairment

Interventions

DRUG

Olorofim

single oral dose

Trial Locations (2)

32809

Orlando Clinical Research Centre, Orlando

92780

Orange County Research Centre, Tustin

Sponsors

Lead Sponsor

F2G Biotech GmbH

All Listed Sponsors

lead

F2G Biotech GmbH

INDUSTRY